30 Day Trial
ORTHOKNOW logo

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

4Q13/2013 Revenue: Anika Therapeutics

4Q13 revenue: $15.3MM, -22%

2013 revenue: $55.9MM, +12%

  • U.S. ORTHOVISC +21% (Mitek revenue +9%)
  • Ex-U.S. viscosupplementation +34% (ORTHOVISC +30%, MONOVISC +50%)

 

  • Growth fueled primarily by ORTHOVISC U.S. and ex-U.S.; claims #2 U.S. viscosupplementation product market share
  • Ex-U.S. growth supported by Canada, Middle East
  • Launching Hyalofast cartilage regeneration human clinical trial
  • Completed enrollment in Cingal Phase III clinical trial, seeks to submit CE Mark application by end of 2014

 

Received FDA approval for MONOVISC in knee OA:

  • 1st approved 1-injection product with HA from non-animal source
  • U.S. commercial launch planned by end of 1Q14
  • Doesn’t expect product to significantly cannibalize ORTHOVISC
  • Indications for other joints would require additional PMA clinical trials